Objective: The harmonization of core outcome domains in clinical trials facilitates comparison and pooling of data, and simplifies the preparation and review of research projects and comparison of risks and benefits of treatments. Therefore, we provide recommendations for the core outcome domains that should be considered in clinical trials on the efficacy and effectiveness of interventions for somatic symptom disorder, bodily distress disorder, and functional somatic syndromes. Methods: The European Network on Somatic Symptom Disorders group of more than 20 experts in the field met twice in Hamburg to discuss issues of assessment and intervention research in somatic symptom disorder, bodily distress disorder, and functional somatic syndromes. The consensus meetings identified core outcome domains that should be considered in clinical trials evaluating treatments for somatic symptom disorder and associated functional somatic syndromes. Results: The following core domains should be considered when defining ascertainment methods in clinical trials: a) classification of somatic symptom disorder/bodily distress disorder, associated functional somatic syndromes, and comorbid mental disorders (using structured clinical interviews), duration of symptoms, medical morbidity, and prior treatments; b) location, intensity, and interference of somatic symptoms; c) associated psychobehavioral features and biological markers; d) illness consequences (quality of life, disability, health care utilization, health care costs; e) global improvement and treatment satisfaction; and f ) unwanted negative effects. Conclusions: The proposed criteria are intended to improve synergies of clinical trials and to facilitate decision making when comparing different treatment approaches. These recommendations should not result in inflexible guidelines, but increase consistency across investigations in this field.
INTRODUCTION
A scertainment methods, addressed domains, and outcome reports in intervention trials on bodily distress disorder (BDD), somatic symptom disorder (SSD)/somatoform disorders, and functional somatic syndromes vary substantially. This has impeded evaluations of the efficacy and effectiveness of suggested treatment approaches. Current interventions on somatic symptom and associated disorders reveal moderate effect sizes for psychological (1, 2) and pharmacological interventions such as tricyclic antidepressants (3) , which can be a result of not only moderately effective treatments but also flaws of assessment strategies. Agglomeration of results of intervention trials (e.g., in meta-analyses) is blurred by assessment tools that are not sufficiently evaluated by their sensitivity to assess change, by a large variability of assessment tools, by a lack of including relevant core domains for comparability, and by other factors (2, 4) .
The development of a core set of outcome domains and quality criteria has been shown to improve comparison and pooling of data of intervention trials, while leaving investigators free to extend the core set with other instruments of their choice. In pain research, the introduction of the criteria provided by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) criteria (5-7) led to a substantial improvement of the comparability and potential for accumulation of clinical trials. The introduction of quality criteria for intervention studies, such as the CONSORT criteria or the quality criteria of Cochrane analyses, substantially improved the average quality of published clinical trials and reduced the risk of publication of false-positive results. In the field of BDD, SSD, and functional somatic syndromes, the development of a recommended core set of outcome domains is still lacking, although assessment recommendations for single functional somatic syndromes have been published (e.g., for fibromyalgia (8) ). Therefore, the European Network on Somatic Symptom Disorders (EURONET-SOMA) aimed to find a consensus for core domains to be assessed in the evaluation of interventions in the general field of somatic symptoms and associated disorders.
METHODS
Two meetings of more than 20 European experts took place in Hamburg (Germany) and were organized by Bernd Löwe and his team in 2016. Several subgroups addressed different topics of research in SSD. Members of this subgroup were experienced in the conduct of clinical trials and aggregation of different trial results. During the first session, we defined the clinical conditions of interest. After discussing different options, a consensus was reached to address SSD, BDD, and associated functional somatic syndromes. Reasons for this decision were the fact that these syndromes claim to describe specific clinical conditions, although they are highly overlapping. The concept of SSD is defined in Diagnostic and Statistical Manual for Mental Disorders, Fifth Edition (DSM-5); BDD was originally defined by the Danish group of Fink (9, 10) , and it was shown that this definition covers most forms of somatization and functional somatic syndromes. For several functional somatic syndromes, current definitions and classification criteria exist (e.g., ROME-IV criteria for irritable bowel syndrome (IBS) (11, 12) ; fibromyalgia criteria (13) ). To develop a consensus for assessment domains, we analyzed the following: IMMPACT criteria; results of Cochrane and other meta-analyses in the field of SSD or BDD; recommendations for outcome measurement in specific syndromes, such as IBS and fibromyalgia; general recommendations about the assessment of change in psychosomatic, psychiatric, and psychological research; and specific results on the quality of assessing change of various assessment tools (e.g., Ref. (14)). All participants of this specific working group were invited to name existing recommendations for outcome measurements of the corresponding groups. These nominations were collected and grouped to domains. The resulting proposal of domains was presented during the second meeting and was further discussed. These discussions led to further adaptations. After the second meeting, the resulting proposal was circulated twice to find a general agreement. Afterward, this agreement was further circulated to the overall group and was finally harmonized. The final proposal was accepted by all group members. Of note, although recommendations for the assessment of trait variables and current state variables of somatic symptoms in particular for epidemiological research have been published elsewhere (4), more specific challenges of selecting tools for the assessment of change are addressed in this article.
RESULTS
All clinical trials of this field should consider reporting in agreement with the general quality criteria for clinical trials, such as the CONSORT criteria, with their specific recommendations. In particular, the description of interventions, the selection of participants, inclusion and exclusion criteria, the definition of concurrent treatments, the assessment of treatments during follow-up periods, randomization and blinding procedures, statistical management of missing values and dropouts, adherence to treatment guidelines, and so on, are crucial prerequisites to evaluate scientific rigor and clinical implications of these trials.
The CONSORT criteria suggest defining specific primary outcome variables. In addition to identifying the primary outcome of a trial, present recommendations add a broad variety of assessment domains relevant to SSD/BDD, to facilitate the comparison and agglomeration of different clinical intervention effects. To accomplish this goal, we had to consider the broad variety of diagnoses, concepts, and approaches of this clinical group. We recommend the following domains to be addressed in clinical trials (for an overview, see (18) can offer an economic alternative. In any case, a clear description of the selected sample and consideration of inclusion and exclusion criteria requires the use of one of these types of instruments. Although a clear description of inclusion criteria is a prerequisite of high-quality trials, investigators should be aware of the tremendous overlap of symptom profiles and other characteristics of functional somatic syndromes (10, 19) . Therefore, it is crucial to use broad-spectrum assessments for multiple symptoms or multisymptomatic syndromes in addition to focusing on any particular symptom profile. Symptom onset, symptom duration, and treatment preexperiences should be additionally investigated. A reassessment at end of treatment and/or follow-up is strongly recommended. In combination with potential expert disability ratings (see later), these ratings should be done by raters blinded to the treatment selected for this patient-this could lead to expert ratings of remission and response rates.
The diagnosis of SSD according to DSM-5 and the current ICD-11 proposal of BDD do not exclude the existence of comorbid medical conditions. SSD can be used as a diagnosis even if all somatic symptoms are explained on the background of a medical disease, such as cancer, because for the SSD diagnosis, the burden of the symptoms is more relevant than the postulated etiology. Several functional somatic syndromes require that their core symptoms (e.g., abdominal pain in case of IBS) are not mainly explained by a general medical disease. Nevertheless, also these functional somatic syndromes often co-occur with physical diseases. Moreover, co-occurring medical conditions influence other relevant clinical outcome measures and health care use (20) . Therefore, it is crucial to assess the co-occurrence of physical diseases carefully. Binary checklists for somatic illnesses, such as the World Health Organization checklist of chronic diseases in the Schedules for Clinical Assessment in Neuropsychiatry (17), help to ensure that a comprehensive description of the somatic and psychological dimensions of the patient's medical status is given. In more severely affected or inpatient samples, the updated Charlson comorbidity index could also be relevant (21) . Depending on the research question, repeated measurement could be useful.
Assessment of somatic symptoms
Although DSM-5 has shifted the focus of classification from the assessment of somatic symptoms to the consideration of concurrent psychosocial factors, clinical trials should continue to assess the different facets of somatic symptoms (e.g., multiplicity of symptoms, location and type of symptoms, intensity, occurrence, duration, and interference with daily activities) as change in symptoms will continue to be a central outcome feature of treatments for patients and physicians/therapists alike.
Although more sophisticated assessment tools are also necessary, we recommend the use of two numeric rating scales (NRSs; see Fig. 1 and Appendix, Supplemental Digital Content 1, http://links.lww.com/PSYMED/A408) to assess
• symptom intensity and • symptom interference with daily activities.
The field of pain research has strongly benefited from using these two simple-to-use NRSs. It allows for comparison of the efficiency of interventions between clinical trials. NRSs have been shown to be sensitive to the assessment of change, valid, and simple to use (22) . A commonly used time frame for assessing somatic symptoms with an NRS is 7 days.
Self-rating scales should be used that are specifically evaluated to assess changes of somatic symptoms. Although the Patient Health Questionnaire is one of the most frequently used instruments to identify people at risk for somatization, its sensitivity to assess change was only sparsely evaluated (23) . However, it has shown treatment effects in some evaluation trials (e.g., Ref. (24)). The somatization subscale of the Symptom Checklist is also frequently used, albeit its specificity for SSD is less clear (25) . The Screening for Somatoform Symptoms has been evaluated for the sensitivity to assess change (26) , but represents a very broad assessment tool. The Bradford Somatic Inventory claims to be valid for multiple ethnic groups (27) , which is an aspect that was frequently neglected during assessment tool evaluation. The Bodily Distress Syndrome Checklist has been validated as a screening tool for bodily distress syndrome (28) , but its sensitivity to assess change needs further evaluation.
In contrast to pain research, symptom diaries and other experience sampling methods are less frequently used in the field of SSD or BDD. However, they could provide information that goes far beyond self-rating scales, and new technologies are further facilitating their application (29) (e.g., ecological momentary assessments). Multiple assessments allow for the analysis of patterns of change and the use of time-lag analyses. If diaries are used, it is recommended not only to use "negative" items (e.g., current symptom intensity) but also to address positive features (e.g., current ability to cope with symptoms and current ability to enjoy life despite of symptoms) (30).
3. Psychobehavioral features DSM-5 introduced classification-relevant psychobehavioral features of SSD, such as health anxiety, illness worry, excessive time, and energy spent on the symptoms or health concerns. Therefore, these features are part of the classification process (domain 1), but often, they also determine significant parts of the overall suffering of patients, and they also belong to potential mechanisms of symptom development and symptom maintenance. Therefore, they also constitute a core outcome domain. Several assessment tools have been developed to investigate these features. The frequently used Whiteley-Index WI is a well-established and economic instrument to assess health anxiety (31) , but also other instruments have demonstrated sensitivity to assess change in this field (32) . New developments try to cover the full spectrum of the B criteria of SSD (i.e., the cognitive, affective, and behavioral impact of symptoms), for example, the Somatic Symptom Disorder Scale (33) . Again, their sensitivity to assess change has to be further evaluated.
Anxiety and depression are frequently co-occurring psychopathological phenomena. Therefore, the assessment of broader psychopathology beyond somatization is strongly recommended. Typical assessment tools are the Symptom Checklist, the anxiety and depression subscales of the Patient Health Questionnaire (34-36), or other self-and expert ratings on psychopathology (37, 38) The assessment of psychological features of the disorders should also address potential mechanisms of change/mediators. Somatosensory amplification (39) describes the vicious circle of illness anxieties, attention focusing, and amplified perception of symptoms, and catastrophizing of symptoms (40) . This mechanism shows close relationships to bodily vigilance (41) . Fear avoidance has been shown to be one of the most powerful predictors of the development of symptom persistence/ chronicity (42), and it is considered to be a major maintaining factor for these types of symptoms (43) . Patients can show dysfunctional illness behavior that contributes to the maintenance of symptoms. Many interventions try to improve symptom coping skills, and reduction in fear avoidance or symptom catastrophizing partially mediates treatment effects across various syndromes (44, 45) . These variables should be addressed accordingly. Illness beliefs in general, such as assumptions about the etiology of symptoms, suspected medical explanations, expected course, and treatment responses, are examples of components of illness beliefs. Some of these components can be dysfunctional (e.g., in contributing to high health expenditures (46) ) and need to be changed during interventions. A typical instrument to assess these illness beliefs is the Illness Perception Questionnaire (47), which is also available in a shortened version (48) . However, depending on the rationale of the treatment approach, other mechanisms of change can be postulated and should be assessed accordingly (e.g., emotion regulation, attachment insecurity (49), reduction of avoidance behavior, reduction of symptom reinforcement via relatives, increase of acceptance and mindfulness, and communication skills). The assessment of mediators could be complemented with the evaluation of potential moderators (e.g., personality traits such as neuroticism or negative affectivity, gender, and age).
Illness consequences (quality of life and disability assessment)
Health-related quality of life (HrQoL) is the most relevant outcome domain in this field, and its assessment should address issues such as physical functioning, and psychological and emotional functioning, but also functioning in social roles. The most frequently used assessment tool for HrQoL is the Short Form (SF)-36, or its abbreviated version SF-12 (50, 51) . This instrument has been specifically adapted for the use in the field of SSD (52). As an alternative or extension to the assessment of HrQoL, assessments of disability are highly recommended. A frequently used assessment tool that is both economic and valid to assess change is the Pain Disability Inventory, which has been adapted to somatic symptoms in general (53) . Also frequently used are the Sheehan Disability Scales (54) . Finally, health care costs and health care utilization are considered to be of pivotal relevance in somatization syndromes, in particular because a substantial subgroup of patients is characterized by continuous health care seeking. Although variables of health care use and costs are notoriously associated with statistical distribution and evaluation problems, their financial relevance should motivate to address this issue in clinical trials. In combination with health economic research questions, the assessment of quality-adjusted life years is needed. For this purpose, instruments such as the European Quality of Life Group (EQ-5D; (55)) or the SF-6D (56) can be used as an alternative to the SF-36. Recently, the Recovering Quality of Life Screener has been developed which has been validated to give a better assessment of quality of life in mental disorders (www.reqol.org.uk/p/overview.html).
Consumer satisfaction
A global rating on treatment success from the perspective of the patient is also highly recommended. It is obvious that the definition of improvement by a patient can substantially differ from the improvements shown in symptom scales, or as evaluated via clinical expert ratings. In addition, treatment satisfaction can also represent a variable that is of substantial relevance but not identical to other suggested variables. The "recommendation item" ("Would you recommend this treatment to another person/a friend with similar problems?") is one possible simple item that could be used in all clinical trials to assess treatment satisfaction. Consumer satisfaction scales have been developed for other clinical fields (57) but can be easily adapted to the target group of this article.
The effect of psychological interventions strongly depends on factors such as credibility of treatment, therapeutic relationship, and expectation of improvement. Therefore, their assessment is recommended if psychological interventions are compared and evaluated. A brief scale to address these topics has been suggested (58) . For the assessment of the quality of the therapeutic relationship, several screeners have been published (e.g., Refs. (59,60) ).
Unwanted negative treatment effects
A scientifically based treatment recommendation requires an evaluation of the expected positive treatment effects in relation to potential negative outcomes. However, even in pharmacology research, side effects are frequently assessed with unsatisfactory methods (61, 62) . Over the last century, psychotherapy research has also neglected the issue of unwanted negative effects (63) . However, considering the vulnerable states of many patients with SSD/BDD as well as the many problematic experiences that patients report from past treatments, it is strongly recommended to assess unwanted negative effects during and after treatment. It is not considered sufficient just to add one or two open questions, and to rate their answers by experts about their relevance, as was frequently done in pharmacology research (64) . More systematic assessments for negative effects are required both in psychological intervention trials and in pharmacological intervention trials; just recently, assessment tools to ascertain negative effects of psychotherapy have been developed, although this field is just at the beginning of validating corresponding instruments (65, 66) . In pharmacological trials, systematic and structured assessments should complement registrations that are more spontaneous and observation based (66, 67) .
DISCUSSION
In this article, we present consensus recommendations on which domains should be covered when planning the assessment tools in clinical trials in the field of SSD, BDD, and functional somatic syndromes. Although such a multidimensional approach should not replace other quality criteria of clinical trials (such as the definition of primary outcome variables), it should facilitate the comparability between clinical trials and help optimize the accumulation of results from different trials, for example, in meta-analyses or Cochrane analyses.
A harmonization of assessments between clinical trials has the potential to substantially improve not only trial quality per se but also the synergistic potentials between trials. It would be extremely helpful to have at least one or two very simple assessment methods that should be part of most clinical trials such as two suggested NRSs on symptom intensity and interference with daily activities respectively (domain 2). Moreover, the definition of domains should also help to decrease the notorious lack of information, as soon as the primary variables are analyzed in metaanalyses. When features such as comorbid emotional problems, psychobehavioral features (domain 3), and illness consequences (quality of life and disability; domain 4) are subject of agglomeration of trials, often less than 30% of the original trials provide full data (1). In such a situation, where most published trials cannot be used, scientific and clinical progress will be unnecessarily delayed, and most conclusions from clinical trials must remain incomplete. Moreover, a systematic consideration of potential mediators and moderators of interventions offers a basis for targeted treatment decisions. Therefore, we expect a major breakthrough if these recommendations are considered in future clinical trials.
Although the IMMPACT and CONSORT criteria offer stimulating and thoughtful recommendations, a specific adaptation to the field of SSD, BDD, and functional somatic syndromes is necessary. CONSORT offers a general quality framework for all clinical trials, which needed to be more specified for the field of interest of this article. Specific domains of necessary ascertainments beyond the definition of primary and secondary outcome variables, and side effects are not specified in CONSORT criteria but in our article. IMMPACT has a strong focus on specific pain syndromes. Although pain syndromes are also of relevance for many functional somatic syndromes, the scope has to be broadened to include SSD, BDD, and functional somatic syndromes to address the multiplicity of symptoms, the large overlap between different functional somatic syndromes, and to the fact that for some functional somatic syndromes, non-pain symptoms are crucial (e.g., chronic fatigue and multiple-chemical sensitivity syndrome). Therefore, not surprisingly, some recommendations of our approach show similarity to IMMPACT recommendations (e.g., physical and emotional functioning, participant ratings of improvement and satisfaction with treatment, and symptoms and adverse events), whereas others are adapted to our field of interest (e.g., classification issues, how to address somatic conditions, addressing overlap between functional somatic syndromes, and distinction between illness consequences and psychobehavioral mechanisms).
Another advantage of the EURONET-SOMA recommendations is the inclusion of frequently neglected, yet highly relevant variables. The neglect of assessing unexpected negative effects in clinical trials investigating psychological interventions is one of the most impressive examples of blind spots in clinical research. However, if interventions increase the risk of somatic symptom turbulences, emotional crisis, or suicidal ideation, or if patients feel that they are not taken seriously, such an intervention should be considered more critically compared with other interventions with similar benefits, but fewer of these negative effects. Therefore, an adequate benefit-risk evaluation requires the assessment not only of treatment advantages but also of treatment-related problems (domain 5). These unwanted treatment outcomes may also influence patients' consumer satisfaction of the intervention, which is another important outcome (domain 6).
When summarizing these recommendations, it also became evident that cultural adaptations of instruments are mostly lacking. This is all the more problematic because somatic symptoms are embedded and experienced in the context of culture and language and thus differ in terms of type, location, intensity, and ways of communicating them. Most intervention trials included patients with diverse backgrounds, and these effects of diversity can further add to uncontrolled variance if instruments are used without cultural equivalence or adaptation.
Publishing recommendations always bears the risk of overstandardization, whereas research progress needs some competition between conflicting approaches. Our aim is to provide a set of domains that are advantageous to address, rather than setting strict standards for future trials. Although we mention several specific assessment tools, this is only done to highlight examples for the field, whereas the genuine recommendations primarily cover the six core domains. It remains up to the investigators not only to select assessment tools for these domains but also to extend the suggested domains with other fields of interest. However, we want to encourage the use of multimethodological approaches: the use of expert ratings can easily lead to overestimations of intervention effects and should always be complemented with validated self-ratings focusing on patient's perspective (68, 69) .
Moreover, we want to emphasize that in addition to statistical significance, clinical significance should be considered. Clinical significance accounts for the clinical relevance of individual patient's response to a treatment. There are many different methods of analyzing clinical relevance. For continuous data, the reliable change index has been recommended because it incorporates the standard error of the measurement depending on the measurement's reliability. However, the cutoff of the reliable change index is greater than 1.96, indicating that reliable change is not feasible for the assessment of change of somatic symptom intensity and is highly dependent on the variability of the assessment tool as well as the correlation of the assessment tool over repeated measures. For dichotomous data, the number needed to treat for another beneficial outcome is often used, which is defined as the number of participants that needed to be treated for one to benefit in a given time frame. Because clinical significance regarding the outcome domains has not been examined sufficiently for our field, empirical criteria of clinically significant change cannot be provided. We refer to a recommendation by the IMMPACT which provides provisional criteria for interpreting the clinical importance of treatment outcomes in clinical trials of patients with chronic pain (70) . For example, a decrease of 30% on a 0-10 NRS measuring pain intensity was defined as a moderately important change, and a decrease of at least 50% as a substantial improvement. The proposed multidomain assessments will enable investigation of whether such improvements are paralleled by changes in other domains relevant to SSD, BDD, and functional SSDs.
For the evaluation of clinical trials, there is no need to show improvements on all recommended domains for a single intervention, and in most cases, it will be essential to establish an a priori primary outcome measure. However, it is important to realize that treatment effects can differ substantially between the specific domains. Treatments can substantially improve quality of life, although not change symptom intensity (e.g., if the focus is on acceptance strategies). The relevance of specific core domains can also vary depending on selection criteria and aim of the study: if, for instance, patients with abnormal health care use are selected for treatments, the effects on health care utilization can be of more relevance than the effect on comorbid emotional problems. Moreover, the relevance of each domain partially depends on one's theoretical perspective or clinical interest. For referring physicians, the improvement of symptoms could be of major interest, whereas the reduction of health care utilization could be more relevant for health care insurances. Similarly, working ability and role functioning are crucial from a societal perspective, and for the patient and significant others, issues related to life satisfaction are likely to be essential treatment outcomes. These examples highlight that the recommended core domains reveal relevant and necessary information to evaluate a specific treatment of interest in comparison to other treatments and to reveal the relevant information for the specific interest group.
Although the IMMPACT criteria of pain research stimulated the development of the EURONET-SOMA criteria, the later ones try to extend this proposal and to tailor it specifically to the field of SSD, BDD, and functional somatic syndromes. Specific recommendations on how to address the diversity of included syndromes, how to address comorbid medical conditions, or how to assess unwanted negative effects of interventions are included. Beyond these more specific recommendations, the attempt to harmonize domains of evaluation methods is expected to accelerate progress of intervention research in this field. Therefore, we anticipate that the recommendations of core domains for outcome assessment in clinical trials of SSD will result in more consistency in trial design and output assessment, with the goal of improving interpretability and generalizability of clinical trials in this field.
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